# Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients

> **NCT00254163** · PHASE3 · COMPLETED · sponsor: **US Oncology Research** · enrollment: 184 (actual)

## Conditions studied

- B-Cell Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Rituximab
- **DRUG:** Pentostatin

## Key facts

- **NCT ID:** NCT00254163
- **Lead sponsor:** US Oncology Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2016-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00254163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00254163, "Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00254163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*